These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 9748116)

  • 21. Dose-dense chemotherapy for primary breast cancer.
    Kümmel S; Rezai M; Kimmig R; Schmid P
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Blayney DW; McGuire BW; Cruickshank SE; Johnson DH
    Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
    Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
    Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mitoxantrone: its development and role in clinical practice.
    Weiss RB
    Oncology (Williston Park); 1989 Jun; 3(6):135-41; discussion 141-3, 147-8. PubMed ID: 2701571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity.
    Hryniuk W; Frei E; Wright FA
    J Clin Oncol; 1998 Sep; 16(9):3137-47. PubMed ID: 9738586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of theoretical models to chemotherapy protocol design.
    Goldie JH; Coldman AJ
    Cancer Treat Rep; 1986 Jan; 70(1):127-31. PubMed ID: 3510731
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selecting combinations of chemotherapeutic drugs to maximize dose intensity.
    Simon R; Korn EL
    J Biopharm Stat; 1991; 1(2):247-59. PubMed ID: 1844700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response surface methodology and the design of clinical trials for the evaluation of cancer chemotherapy.
    Carter WH
    Cancer Treat Rep; 1985 Oct; 69(10):1049-53. PubMed ID: 4042084
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug development in solid tumors: personal perspective of Dr. Emil J Freireich's contributions.
    Carbone PP
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2614-22. PubMed ID: 10068263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple testing for a combination drug with two study endpoints.
    Shao J; Zhang S; Zhao J; Chiang A
    Stat Med; 2012 Jul; 31(17):1779-90. PubMed ID: 22576824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug dosage intensity--a panel discussion.
    McGuire WL; Goldie J; Hryniuk W; Tormey DC
    Breast Cancer Res Treat; 1987; 9(2):87-100. PubMed ID: 3620720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dosage parameters in chemotherapy of breast cancer.
    Hryniuk W
    Breast Dis; 2001; 14():21-30. PubMed ID: 15687633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The current approaches to enhancing the efficacy of antitumor chemotherapy by individual treatment optimization and the selective decrease in the toxic side effects of cytostatics].
    Bogush TA; Bogush EA; Stepanov AA
    Antibiot Khimioter; 2000; 45(1):32-8. PubMed ID: 10690426
    [No Abstract]   [Full Text] [Related]  

  • 34. High-potency preparations of pancreatin.
    Drug Ther Bull; 1993 Aug; 31(16):63-4. PubMed ID: 8375276
    [No Abstract]   [Full Text] [Related]  

  • 35. Propranolol, Promising Chemosensitizer and Candidate for the Combined Therapy through Disruption of Tumor Microenvironment Homeostasis by Decreasing the Level of Carbonic Anhydrase IX.
    Puzderova B; Belvoncikova P; Grossmannova K; Csaderova L; Labudova M; Fecikova S; Pastorek J; Barathova M
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitigating acute chemotherapy-associated adverse events in patients with cancer.
    Kuderer NM; Desai A; Lustberg MB; Lyman GH
    Nat Rev Clin Oncol; 2022 Nov; 19(11):681-697. PubMed ID: 36221000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of Reactive Oxygen Species to Overcome 5-Fluorouracil Resistance.
    Chun KS; Joo SH
    Biomol Ther (Seoul); 2022 Nov; 30(6):479-489. PubMed ID: 35440517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of chemotherapy dose intensity for metastatic colorectal cancer.
    Chu X; Xue P; Zhu S
    Oncol Lett; 2022 May; 23(5):141. PubMed ID: 35340557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro evaluation of the anticancer activity of barbituric/thiobarbituric acid-based chromene derivatives.
    Ghadami SA; Hosseinzadeh L; Eskandari E; Yarmohammadi N; Adibi H
    Mol Biol Rep; 2021 Dec; 48(12):7637-7646. PubMed ID: 34741706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials.
    Hirakawa A; Tanaka Y; Kaneko S
    Contemp Clin Trials Commun; 2019 Dec; 16():100489. PubMed ID: 31799475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.